Emerging immunotherapies need harmonization on definitions and monitoring

Turning CAR T cell therapies and T cell engaging bispecific antibodies into cornerstones of cancer immunotherapy will require standardizing the definitions and monitoring systems for the novel toxicities they bring, according to panelists at a Friends of Cancer Research meeting held on Feb. 11.

The meeting gathered policymakers, drug sponsors and academic stakeholders to discuss the future of emerging immunotherapies and cell therapies for cancer, and outlined the reasons that harmonizing data collection around emerging toxicities will benefit regulators, payers and drug developers, as well as patients and providers. ...